Insider Selling: Labcorp (NYSE:LH) EVP Sells 92 Shares of Stock

Labcorp Holdings Inc. (NYSE:LH) EVP Kathryn Kyle sold 92 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total value of $26,329.48. Following the sale, the executive vice president directly owned 3,904 shares in the company, valued at $1,117,285.76. This trade represents a 2.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Labcorp Stock Down 1.3%

LH traded down $3.64 on Monday, reaching $283.34. The company’s stock had a trading volume of 56,019 shares, compared to its average volume of 671,858. The stock has a 50 day moving average of $262.24 and a two-hundred day moving average of $266.27. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $23.23 billion, a price-to-earnings ratio of 25.10, a P/E/G ratio of 2.01 and a beta of 0.89. Labcorp Holdings Inc. has a fifty-two week low of $241.81 and a fifty-two week high of $293.72.

Labcorp (NYSE:LH) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. The company had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the company earned $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, analysts forecast that Labcorp Holdings Inc. will post 18 EPS for the current fiscal year.

Labcorp Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 11th. Investors of record on Friday, May 29th were paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.0%. The ex-dividend date was Friday, May 29th. Labcorp’s dividend payout ratio (DPR) is currently 25.51%.

Hedge Funds Weigh In On Labcorp

Several institutional investors and hedge funds have recently added to or reduced their stakes in LH. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Labcorp during the 4th quarter worth approximately $26,000. Hilton Head Capital Partners LLC acquired a new position in Labcorp during the fourth quarter worth $27,000. JPL Wealth Management LLC acquired a new position in Labcorp during the third quarter worth $28,000. Eagle Bay Advisors LLC purchased a new position in Labcorp in the fourth quarter worth $29,000. Finally, DV Equities LLC purchased a new position in Labcorp in the fourth quarter worth $29,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on LH shares. Robert W. Baird set a $334.00 price objective on Labcorp in a report on Friday, May 1st. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Labcorp in a research report on Friday, May 8th. Evercore reiterated an “outperform” rating and issued a $300.00 price objective on shares of Labcorp in a research note on Wednesday, April 8th. Finally, Wall Street Zen lowered shares of Labcorp from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $308.00.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.